中国科学技术信息研究所--国家工程技术数字图书馆

Efficacy and safety of anlotinib plus S-1as thirdly-line or later-line treatmentin advanced non-small cell lung cancer

[期刊]

《肿瘤学与转化医学:英文版》 2020年1期

原文获取收藏分享

作者	Heng Cao Kai Liang Peng Liu Jing Wang Yuanyuan Ji Lujuan Xu Weilong Wu Shengnan Guo Xuekun Song Yonggui Hong
期刊名称	《肿瘤学与转化医学:英文版》
页码/总页数	P.10-15 / 6
语种/中图分类号	汉语 / R734.2
关键词	non-small cell lung cancer(NSCLC) anlotinib tegafur gimerac advanced stage
DOI	10.1007/s10330-019-0370-0
基金项目	Supported by a grant from the Youth National Science Foundation of China(No.61702164)。

相关论文

Pharmacoeconomic Study on the Treatment of Terminal Non-small Cell Lung Cancer with Icotinib and Pemetrexed Combined with Cisplatin

Significance of Multimodality Therapy in Patients with a Superior Sulcus Tumor of the Lung: A Review Article

TT genotype of GNAS1 T393C polymorphism predicts better outcome of advanced non-small cell lung cancer patients

Association of Polymorphic Variants of VEGFand KDRGenes with Development and Metastasing of Non-Small Cell Lung Cancer

Patient-Reported Outcomes of Chemotherapy Involving Non-Small Cell Lung Cancer: Evaluation by Questionnaires of Quality of Life Regarding Anti-Aging and Anti-Cancer Drugs

相关机构

沈阳药科大学

相关作者

相关关键词